Evidence map›Paper›PMID 30649643›Full record

ArticleClinical and translational medicine2019

The effect of omega-3 fatty acids on clinical and paraclinical features of intractable epileptic patients: a triple blind randomized clinical trial.

Shaghayegh Omrani, Mohammad Taheri, Mir Davood Omrani, Shahram Arsang-Jang, Soudeh Ghafouri-Fard

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical and translational medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed, 1 pooled it
1.4field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 1 synthesis or guideline pooled it, 23 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Review
  4. Review
  5. Article
  6. Review
  7. Article
  8. Review
  9. Review
  10. Review
  11. Article
  12. Review
  13. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

Shaghayegh OmraniDepartment of Neurology, Hamadan University of Medical Sciences, Hamadan, Iran.
Mohammad TaheriStudent Research Committee, Shahid Beheshti University of Medical Sciences, Tehran, Iran. mohammad_823@yahoo.com.ORCID http://orcid.org/0000-0001-8381-0591
Mir Davood OmraniUrogenital Stem Cell Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Shahram Arsang-JangClinical Research Development Center (CRDU), Qom University of Medical Sciences, Qom, Iran.
Soudeh Ghafouri-FardDepartment of Medical Genetics, Shahid Beheshti University of Medical Sciences, Tehran, Iran. s.ghafourifard@sbmu.ac.ir.
Shahid Beheshti University of Medical Sciences · IRHamedan University of Medical Sciences · IRQom University of Medical Science and Health Services · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Long chain omega-3 fatty acids (omega-3 FAs) supplements have been shown to exert beneficial effects in patients with epilepsy through elevation of seizure thresholds and dampening of inflammatory responses. In this triple blind randomized, placebo-controlled parallel group trial of omega-3 FA supplementation, 180 mg eicosapentaenoic acid (EPA) and 120 mg docosahexaenoic acid (DHA) as well as placebo capsules were administered twice a day in 50 patients with refractory seizure during a 16-week period respectively. Seizure frequency and duration were reduced after completion of the treatment in the supplement group. The supplementation resulted in a significant decrease in TNF-α and IL-6 concentrations. Further studies are needed to compare different omega-3 FA compositions and determine the most effective dose and treatment duration as well as the long term benefits of this supplementation.

Indexed as

Clinical trialOmega 3Refractory seizure

Identifiers

PMID30649643
PMCPMC6335228
OpenAlexW2915591063

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.